EP
IOVA icon

Essential Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Essential Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.31K Buy
1,758
+457
+35% +$1.74K ﹤0.01% 1363
2026
Q1 		$4.57K Buy
1,301
+917
+239% +$2.93K ﹤0.01% 1618
2025
Q4 		$1.05K Sell
384
-14
-4% -$32 ﹤0.01% 2017
2025
Q3 		$864 Sell
398
-20
-5% -$47 ﹤0.01% 2064
2025
Q2 		$719 Buy
+418
New +$1.04K ﹤0.01% 1593

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Essential Partners's IOVA Position: Q2 2026 in Review

Essential Partners increased its Iovance Biotherapeutics (IOVA) stake by 35% in Q2 2026, buying an estimated $1.74K and bringing the position to 1,758 shares worth $7.31K. The position accounts for ﹤0.01% of the portfolio, ranked #1363.

Essential Partners first reported a position in IOVA in Q2 2025 and has held it in 5 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Essential Partners held 1,758 shares of Iovance Biotherapeutics worth $7.31K as of Q2 2026.
  • Essential Partners bought 457 Iovance Biotherapeutics shares in Q2 2026, an estimated $1.74K.
  • Iovance Biotherapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1363 holding.
  • Essential Partners first reported a position in Iovance Biotherapeutics in Q2 2025 and has held it in 5 quarters since.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.